Bifogade filer
Release
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Sedana Medical has recently set up a direct sales channel in the UK with its own sales organization. This is part of the previously announced plan to establish itself on the most important markets in Europe prior to a marketing authorization of the drug candidate IsoConDa (Isoflurane) and thus a full approval of the entire therapy inhalation sedation within intensive care.
"We are very pleased that we now can start the work of building a market for inhalation sedation in the UK as well. Of course, it is extra gratifying when we also get a positive response by orders from several interested clinics. As a result, we have taken another step towards realising our vision of making inhalation sedation with IsoConDa and AnaConDa a global standard method for the sedation of mechanically ventilated patients in intensive care," says Christer Ahlberg, CEO Sedana Medical.
The market in brief
Sedana Medical's market consists primarily of mechanically ventilated intensive care patients. The market for sedation of mechanically ventilated intensive care patients today consists of established drugs that are administered intravenously. The target group the Company is focusing on are those patients who are ventilated for more than 24 hours, a target group that globally amounts to between two and four million patients per year. In total, the Company consider this to be a market of SEK 10-20 billion per year, of which Europe accounts for about SEK 6 billion.
For additional information, please contact:
Christer Ahlberg, CEO, Sedana Medical AB
Mobile: +46 70 675 33 30, E-mail: Christer.ahlberg@sedanamedical.com
Sedana Medical is listed on Nasdaq First North in Stockholm
and Erik Penser Bank (+46 8 463 83 00) is certified adviser to Sedana Medical.
_________________________
Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanically ventilated patients. A major clinical registration study is currently ongoing to obtain market approval in Europe for inhalation sedation in intensive care units with the pharmaceutical IsoConDa® (isoflurane)
Sedana Medical has direct sales in the Nordic countries, Germany, France and Spain as well as external distributors in the rest of Europe, Canada, Australia and South Korea. The company headquarters are based in Stockholm, Sweden with R&D operations in Ireland.